Bone Biologics (BBLG) Total Liabilities (2010 - 2026)
Bone Biologics (BBLG) posted quarterly Total Liabilities of $418587.0 for Q4 2025, up 10.82% year-over-year from $377712.0 in Q4 2024, and up 25.22% quarter-over-quarter from $334282.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Total Liabilities (2010 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Total Liabilities for 16 consecutive years, with $418587.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 10.82% year-over-year to $418587.0; the TTM figure through Dec 2025 stood at $418587.0 (up 10.82% YoY), while the FY2025 annual figure was $418587.0, up 10.82% from the prior year.
- Total Liabilities grew to $418587.0 in Q4 2025 per BBLG's latest filing, from $334282.0 in the prior quarter.
- Across five years, Total Liabilities topped out at $15.2 million in Q3 2021 and bottomed at $54913.0 in Q1 2022.
- Historically, Total Liabilities has averaged $2.9 million across 5 years, with a median of $412364.5 in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities slumped 99.61% — and 2023, when it soared 7204.93%.
- Bone Biologics' Total Liabilities stood at $99909.0 in 2021, then surged by 2450.25% to $2.5 million in 2022, then tumbled by 67.37% to $831402.0 in 2023, then slumped by 54.57% to $377712.0 in 2024, then rose by 10.82% to $418587.0 in 2025.
- Business Quant data shows BBLG's Total Liabilities at $418587.0 in Q4 2025, $334282.0 in Q3 2025, and $406142.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | 512,018.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 512,018.00 |
| Dec 31, 2025 | 418,587.00 |
| Sep 30, 2025 | 334,282.00 |
| Jun 30, 2025 | 406,142.00 |
| Mar 31, 2025 | 251,158.00 |
| Dec 31, 2024 | 377,712.00 |
| Sep 30, 2024 | 273,402.00 |
| Jun 30, 2024 | 284,507.00 |
| Mar 31, 2024 | 164,626.00 |
| Dec 31, 2023 | 831,402.00 |
| Sep 30, 2023 | 1.18 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 4.01 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Sep 30, 2022 | 799,475.00 |
| Jun 30, 2022 | 70,636.00 |
| Mar 31, 2022 | 54,913.00 |
| Dec 31, 2021 | 99,909.00 |
| Sep 30, 2021 | 15.18 Mn |
| Jun 30, 2021 | 14.62 Mn |